79313038 - HAEMATOKINE

Information

• Trademark
• 79313038

• Source

• Serial Number

  79313038

• Registration Number

  6823077

• International Classifications

  • 1 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry
  • 5 - Pharmaceutical and veterinary preparations

• Filing Date

  February 05, 2021
  4 years ago

• Registration Date

  August 23, 2022
  2 years ago

• Transaction Date

  December 28, 2022
  2 years ago

• Status Date

  August 23, 2022
  2 years ago

• Published for Opposition Date

  June 07, 2022
  2 years ago

• Location Date

  August 23, 2022
  2 years ago

• Status Code

  700

• Current Location

  PUBLICATION AND ISSUE SECTION

  Employee Name

  STADELI, MARTA ANN

• Attorney Docket Number

  8104.0052TM

  Attorney Name

  Mark E. Olds

  Law Office Assigned Location Code

  N50

• Owners

  • Faron Pharmaceuticals Oy

Case File Statements

• GS0051: Pharmaceuticals, medical and veterinary preparations for the treatment of hematological malignancies, bone marrow dysfunction or suppressions; Sanitary preparations for medical purposes; Stem cells for medical or veterinary use; Stem cells for medical purposes; Tumor suppressing agents; Pharmaceutical preparations, namely, antineoplastics; Anti-neoplastic preparations of chemical origin, namely, pharmaceutical preparations for hematological malignancies, bone marrow dysfunction or suppressions; Anti-neoplastic preparations of microbial origin, namely, pharmaceutical preparations for hematological malignancies, bone marrow dysfunction or suppressions; Anti-cancer preparations; Compounds for treating cancer, namely, anti-cancer preparations; Antibodies for medical purposes for the treatment of hematological malignancies, bone marrow dysfunction or suppressions; Antibodies for medical use to treat inflammation and cancer growth and spread; Adjuvants for medical purposes; Vaccine adjuvants; Biological adjuvants for medical purposes; Anti-inflammatories; Antigens, namely, tumour antigens for medical diagnostic purposes; Biological preparations for the treatment of cancer; Biopharmaceuticals for the treatment of cancer; Biotechnological preparations for medical use, namely, biological preparations for the treatment of conditions associated with poor production of hematopoietic stem cells; Culture media for medical use, namely, culture media for use in augmentation of blood cells, bone marrow and tissues for medical purposes; Media for bacteriological cultures; Cell growth media for growing cells for medical use; Biological preparations for medical purposes, namely, biological preparations for the treatment of hematological malignancies, bone marrow dysfunction or suppressions; Mixed biological preparations for medical purposes, namely, mixed biological preparations for the prevention and treatment of infectious diseases; Biological preparations for veterinary purposes, namely, biological preparations for the treatment of hematological malignancies, bone marrow dysfunction or suppressions; Pharmaceutical preparations, namely, immunomodulators; Immunostimulants; Injectable pharmaceuticals for treatment of hematological malignancies, bone marrow dysfunction or suppressions; Pharmaceutical preparations for the treatment of viral diseases; Pharmaceutical preparations for the treatment of bone diseases; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for activating cellular function; Pharmaceutical preparations for immunity adjustment; Pharmaceutical preparations for regulating the immune system; Pharmaceutical preparations for treating malignant tumors; Pharmaceutical preparations for suppressing tumors; Pharmaceutical preparations for the treatment of autoimmune diseases; Pharmaceutical preparations for the prevention of tumours; Pharmaceutical preparations and substances for use in oncology; Pharmaceutical preparations and substances with anti-inflammatory properties for treatment of hematological malignancies, bone marrow dysfunction or suppressions; Pharmaceutical preparations and substances for the treatment of cancer; Pharmaceutical preparations for the treatment of autoimmune disorders; Pharmaceutical preparations for use in hematology; Pharmaceutical preparations for the prevention of diseases of the immune system; Pharmaceutical preparations for the prevention of disorders of the immune system; Pharmaceutical preparations for the prevention of autoimmune diseases; Pharmaceutical preparations for the treatment of disorders caused by bacteria; Pharmaceutical preparations for the treatment of diseases caused by bacteria; Pharmaceutical preparations for the prevention of disorders of the respiratory system; Pharmaceutical preparations for the prevention of inflammatory disorders; Pharmaceutical preparations for the prevention of autoimmune disorders; Pharmaceutical preparations for the prevention of inflammatory diseases; Pharmaceutical preparations for the treatment of inflammatory diseases; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for use in tissue transplantation; Pharmaceutical products for the treatment of bone diseases; Regulatory proteins for medical use, namely, protein arrays for medical diagnosis purposes; Serotherapeutic medicines, namely, pharmaceutical preparations for the treatment of hematological malignancies, bone marrow dysfunction or suppressions; Synthetic peptides for pharmaceutical purposes for the treatment of hematological malignancies, bone marrow dysfunction or suppressions; Pharmaceutical products for treating respiratory diseases; Pharmaceutical compounds for treating respiratory diseases; Pharmaceutical preparations for treating respiratory diseases; Pharmaceutical compounds for treating correlated pulmonary syndromes; Pharmaceutical preparations for treatment and prevention of ischemic conditions, inflammation and organ damages resulting from tissue traumas, reperfusion injuries, cancer, cancer metastasis, inflammatory conditions and allergic conditions; Pharmaceutical preparations for treatment and prevention of multi-organ failure, acute lung injury and acute respiratory distress syndrome in adults, adolescents, children, infants and neonates
• GS0011: Chemicals for use in industry, science and photography, as well as in agriculture, horticulture and forestry, except fungicides, herbicides, insecticides and parasiticides; Biological preparations for use in industry and science; Media for cell culture for use in the biotechnological industry, namely, cell culture media for scientific and research use; Media for cell culture for use in non-medical research laboratories, namely, cell culture media for laboratory use; Biological preparation for use in cell cultures other than for medical or veterinary use; Culture media for microbiology, for scientific and research use; Cell growth media for growing cells for scientific use; Biological preparation for use in cell cultures, other than for medical or veterinary use; Cultures of cell media other than for medical or veterinary use, namely culture media for scientific and research use; Cultures of microorganisms, other than for medical and veterinary use; Blood culture media being cell culture media for scientific use; Biological preparations for use in cell cultures, other than for medical or veterinary purposes; Stem cells, other than for medical or veterinary purposes; Stem cells for scientific purposes; Stem cells for research purposes

Case File Event Statements

• 12/28/2022 - 2 years ago

  35 - FINAL DECISION TRANSACTION PROCESSED BY IB Type: FINO

• 12/1/2022 - 2 years ago

  34 - FINAL DISPOSITION NOTICE SENT TO IB Type: FICS

• 12/1/2022 - 2 years ago

  33 - FINAL DISPOSITION PROCESSED Type: FIMP

• 11/23/2022 - 2 years ago

  32 - FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Type: FICR

• 8/23/2022 - 2 years ago

  31 - NOTICE OF REGISTRATION CONFIRMATION EMAILED Type: NRCC

• 8/23/2022 - 2 years ago

  30 - REGISTERED-PRINCIPAL REGISTER Type: R.PR

• 6/7/2022 - 2 years ago

  29 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB

• 6/7/2022 - 2 years ago

  28 - PUBLISHED FOR OPPOSITION Type: PUBO

• 5/18/2022 - 2 years ago

  27 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP

• 4/29/2022 - 2 years ago

  26 - ELECTRONIC RECORD REVIEW COMPLETE Type: FIXD

• 4/16/2022 - 2 years ago

  25 - CHANGE OF NAME/ADDRESS REC'D FROM IB Type: ADCH

• 4/1/2022 - 2 years ago

  24 - ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED Type: ERRR

• 3/30/2022 - 2 years ago

  23 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA

• 3/30/2022 - 2 years ago

  22 - EXAMINER'S AMENDMENT ENTERED Type: XAEC

• 3/30/2022 - 2 years ago

  21 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN

• 3/30/2022 - 2 years ago

  20 - EXAMINERS AMENDMENT E-MAILED Type: GNEA

• 3/30/2022 - 2 years ago

  19 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA

• 3/25/2022 - 2 years ago

  18 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 3/25/2022 - 2 years ago

  17 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 3/25/2022 - 2 years ago

  16 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA

• 3/18/2022 - 2 years ago

  15 - APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Type: CHAN

• 3/18/2022 - 2 years ago

  14 - TEAS CHANGE OF CORRESPONDENCE RECEIVED Type: TCCA

• 3/18/2022 - 2 years ago

  13 - TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS Type: ECDR

• 3/18/2022 - 2 years ago

  12 - ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Type: ARAA

• 3/18/2022 - 2 years ago

  11 - TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Type: REAP

• 3/18/2022 - 2 years ago

  10 - TEAS CHANGE OF OWNER ADDRESS RECEIVED Type: COAR

• 10/25/2021 - 3 years ago

  9 - REFUSAL PROCESSED BY IB Type: RFNT

• 9/27/2021 - 3 years ago

  8 - NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Type: RFCS

• 9/27/2021 - 3 years ago

  7 - REFUSAL PROCESSED BY MPU Type: RFRR

• 9/9/2021 - 3 years ago

  6 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Type: RFCR

• 9/8/2021 - 3 years ago

  5 - NON-FINAL ACTION WRITTEN Type: CNRT

• 8/30/2021 - 3 years ago

  4 - ASSIGNED TO EXAMINER Type: DOCK

• 6/16/2021 - 3 years ago

  3 - APPLICATION FILING RECEIPT MAILED Type: MAFR

• 6/12/2021 - 3 years ago

  2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM Type: NWOS

• 6/10/2021 - 3 years ago

  1 - SN ASSIGNED FOR SECT 66A APPL FROM IB Type: REPR